NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for fatty liver in early trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive either the drug or a placebo to see if it safely reduces liver fat over 24 weeks. The goal is to find a new treatment that controls…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug shows promise for fatty liver disease in early trial
Disease control Recruiting nowThis early-phase study tests whether the drug miricorilant can lower fat production in the liver for people with MASH, a common liver condition linked to metabolism. Eight participants will take the drug for 6 weeks, and researchers will measure changes in liver fat using scans a…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC